Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET

Company Participants

John Woolford - IR, Westwicke

Daniel O'Connell - President & CEO

Eric Siemers - Chief Medical Officer

Matt Zuga - CFO & Chief Business Officer

Conference Call Participants

Operator

Operator

Thank you for standing by, and welcome to the Acumen Pharmaceuticals, First Quarter 2022 Update Call. At this time, all participants are in a listen-only mode. There'll be a brief overview followed by a question-and-answer session. [Operator Instructions] Today's call is being recorded.

And I would now like to turn the call over to John Woolford from Westwicke. Please go ahead.

John Woolford

Thank you, operator good afternoon. Thank you for joining us today to review Acumen’s first quarter 2022 update on operational progress and financial results. Before we start, we encourage you to read the operational and financial results press release issued this afternoon, which is accessible on our website in the Investors section.

Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. All these statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Our actual results could differ materially due to a number of factors, including the extent and duration of the effects of the COVID-19 pandemic and the timing and extent of recovery from it. Please refer to our recent filings with the SEC for a full review of the risks and uncertainties associated with our business. Forward-looking statements speak only as of the date on which they are made and Acumen undertakes no obligation to update or revise any forward-looking statements.

Daniel O'Connell, President and Chief Executive Officer will begin today's call with a review select first quarter 2022 business highlights and provide an update on the ongoing INTERCEPT-AD trial. Dr. Eric Siemers, Chief Medical Officer will then discuss the recent Frontiers in Science article for ACU193. Next Matt Zuga, Chief Financial Officer and Chief Business Officer will provide a brief financial update. We will then open the call for Q&A.

I'll now hand the call over to Dan O'Connell, President and Chief Executive Officer. Dan?

Daniel O'Connell

Thank you, John. Good afternoon and thank you to everyone joining the call today. I'm delighted to be here to review our first quarter and recent progress. We hosted our first public conference call in late March and during that call, we provided a review of our science the significant differentiation of ACU193 for the potential treatment of Alzheimer's disease.